Indication

Fibrillary Glomerulonephritis

1 clinical trial

1 product

Clinical trial

A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Status: Recruiting, Estimated PCD: 2026-05-01

Product